Melanotan 2 before and after: Frequently asked questions

Uneven tanning reflects localized melanocyte density variation or inconsistent UV exposure patterns. Face and shoulders typically darken faster than torso due to higher MC1R receptor concentration in sun-exposed skin. Rotate UV exposure to cover all areas evenly, and avoid spot-treating specific body parts with additional peptide. Systemic circulation distributes MT-2 uniformly, so injection site doesn't determine tanning location.

Reduce dose by 50% immediately and reassess tolerance after three injections at the lower amount. Persistent nausea indicates MC4R overstimulation in the area postrema (the brainstem's chemoreceptor trigger zone). Most users adapt within 5–7 days at a given dose, so nausea extending past 10 days suggests the dose exceeds your individual tolerance threshold. Consider splitting daily dose into two smaller injections 8–12 hours apart to blunt peak plasma concentration.

Increase UV exposure first, not dose. MT-2 primes melanocytes but requires UV activation to produce visible pigment. Injecting higher doses without sun or tanning bed sessions won't deepen color. Add 5–10 minute controlled UV sessions 2–3 times weekly and reassess after one additional week. If still no change, verify peptide purity and storage conditions (lyophilized powder stored at 2–8°C, reconstituted solution used within 30 days).

Transition to maintenance dosing at 0.25–0.5mg twice weekly once plateau pigmentation is achieved (typically week 4–6). This sustains MC1R activation without the cumulative dose escalation that increases side effect risk. Maintenance requires occasional UV exposure (1–2 sessions weekly) to preserve active melanin distribution. Without UV, even maintenance dosing won't prevent gradual fading over 4–8 weeks.

This is a documented effect of melanocyte hyperactivation in pigmented lesions and typically does not reverse after stopping MT-2. If cosmetically concerning, discontinue use and consult a dermatologist for lesion assessment. Any mole showing irregular borders, asymmetry, or rapid size change requires professional evaluation regardless of peptide use. MT-2 does not cause melanoma, but it can darken pre-existing lesions, making visual monitoring more difficult.

This is the expected response. Melanocytes in nevi and freckles already produce more melanin than surrounding skin, and MC1R activation amplifies that difference. Moles can darken from light brown to near-black within 7–14 days of initiating standard loading protocols. If the cosmetic result concerns you, reduce the dose or discontinue use. The darkening will fade over 4–8 weeks post-discontinuation, though some case reports describe darkened nevi persisting for 3–6 months. Document any mole changes with photos and dates. If you later present for dermatologic screening, the history of Melanotan-2 use is clinically relevant context.

Continue dosing. Melanin production begins within 48 hours, but visible pigmentation requires 5–7 days for melanin-containing keratinocytes to migrate from the basal layer to the stratum corneum. Subjects with Fitzpatrick Type IV or higher skin often see minimal visible change even at week two because baseline melanin is already elevated, and the incremental increase from peptide administration produces little perceptual contrast. If you're experiencing nausea and flushing but no visible tanning by day 10, you're likely a low-responder. Increasing the dose will worsen side effects without proportionally increasing pigmentation.

Reduce the dose by 50% or extend the interval between injections from daily to every other day. Nausea is mediated by MC4R activation in the hypothalamus and area postrema (the brainstem's chemoreceptor trigger zone), and it typically diminishes in severity after 7–14 days due to receptor desensitization. But 10–15% of users experience persistent GI side effects that don't resolve with continued use. Taking the injection before bed can mitigate the impact since the nausea peak (30–90 minutes post-injection) occurs during sleep, but this doesn't reduce the physiological effect, only the subjective experience. If nausea persists beyond two weeks at reduced dose, discontinue use. The cosmetic benefit doesn't justify ongoing GI distress.